pentapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Individuals with BPD express higher levels of jealousy towards their partners in romantic relations. Manipulative behavior to obtain nurturance is considered by the DSM-IV-TR and many mental health professionals to be a characteristic of borderline personality disorder. In one research study, 88% of therapists reported that they have experienced manipulation attempts from patient(s). Marsha Linehan has argued that doing so relies upon the assumption that people with BPD who communicate intense pain, or who engage in self-harm and suicidal behavior, do so to influence the behavior of others. The impact of such behavior on others—often an intense emotional reaction in concerned friends, family members, and therapists—is thus assumed to have been the person's intention. According to Linehan, their frequent expressions of intense pain, self-harming, or suicidal behavior may instead represent a method of mood regulation or an escape mechanism from situations that feel unbearable, however, making their assumed manipulative behavior an involuntary and unintentional response.
== Education == Macor trained as an organic chemist. Macor received his B.S. in chemistry from the University of Notre Dame and his Ph.D. in chemistry from Princeton University in 1986, where he worked under Edward C. Taylor.
=== UV-induced DNA damage === UV-irradiation of human skin cells generates damages in DNA through direct photochemical reactions at adjacent thymine or cytosine residues on the same strand of DNA. Cyclobutane pyrimidine dimers formed by two adjacent thymine bases, or by two adjacent cytosine bases, in DNA are the most frequent types of DNA damage induced by UV. Humans, as well as other organisms, are capable of repairing such UV-induced damages by the process of nucleotide excision repair. In humans this repair process protects against skin cancer.
American Heart Association's Heart Attack web site – Information and resources for preventing, recognizing, and treating a heart attack. TIMI Score for UA/NSTEMI Archived 2016-11-05 at the Wayback Machine and STEMI Archived 2009-03-19 at the Wayback Machine HEART Score for Major Cardiac Events Archived 2016-10-28 at the Wayback Machine "Heart Attack". MedlinePlus. U.S. National Library of Medicine.
== Career == Macor began his industrial career at Pfizer in 1986, where he was a co-inventor of eletriptan, a triptan marketed as Relpax for the acute treatment of migraine. Eletriptan was approved by the FDA in 2002. He later joined Bristol-Myers Squibb in 1997, where he served as executive director of neuroscience chemistry. At Bristol-Myers Squibb, he was a co-inventor in the program that produced the CGRP receptor antagonists rimegepant and zavegepant, which were subsequently developed by Biohaven Pharmaceuticals and approved by the FDA in 2020 and 2023, respectively, for the treatment of migraine. He is also a co-inventor of sparsentan, a dual endothelin and angiotensin II receptor antagonist developed by Travere Therapeutics and approved by the FDA in 2023 for the reduction of proteinuria in adults with IgA nephropathy. Macor’s work at Bristol-Myers Squibb also included the company’s Alzheimer’s disease program, where he contributed to the discovery of avagacestat (BMS-708163), a γ-secretase inhibitor that advanced to Phase 2 clinical trials before development was discontinued. Macor is an author on more than 220 peer-reviewed publications and a named inventor on 150 issued U.S. patents.
Sources: en.wikipedia.org
==== Papillary region ==== The papillary region is composed of loose areolar connective tissue. It is named for its finger-like projections called papillae, which extend toward the epidermis. The papillae provide the dermis with a "bumpy" surface that interdigitates with the epidermis, strengthening the connection between the two layers of skin. In the palms, fingers, soles, and toes, the influence of the papillae projecting into the epidermis forms contours in the skin's surface. These epidermal ridges occur in patterns (see: fingerprint) that are genetically and epigenetically determined and are therefore unique to the individual, making it possible to use fingerprints or footprints as a means of identification.
Suzetrigine, sold under the brand name Journavx, is an analgesic medication used in the treatment of moderate to severe acute pain. It is taken orally. Suzetrigine was developed by Vertex Pharmaceuticals. The most common adverse effects include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash. Suzetrigine is a small-molecule non-opioid analgesic that works as a selective inhibitor of Nav1.8-dependent pain-signaling pathways in the peripheral nervous system. Nav1.8 channels are predominantly present in peripheral nociceptive neurons of the dorsal root ganglia. Suzetrigine inhibits pain signals before they reach the central nervous system and has no addictive potential. Suzetrigine was approved for medical use in the United States in January 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
== Adverse effects == Hydroxychloroquine has a narrow therapeutic index, meaning there is little difference between toxic and therapeutic doses. The most common adverse effects are nausea, stomach cramps, and diarrhea. Other common adverse effects include itching and headache. The most serious adverse effects affect the eye, with dose-related retinopathy as a concern even after hydroxychloroquine use is discontinued. Serious reported neuropsychiatric adverse effects of hydroxychloroquine use include agitation, mania, difficulty sleeping, hallucinations, psychosis, catatonia, paranoia, depression, and suicidal thoughts. In rare situations, hydroxychloroquine has been implicated in cases of serious skin reactions such as Stevens–Johnson syndrome, toxic epidermal necrolysis, and Drug reaction with eosinophilia and systemic symptoms. Reported blood abnormalities with its use include lymphopenia, eosinophilia, and atypical lymphocytosis. For short-term treatment of acute malaria, adverse effects can include abdominal cramps, diarrhea, heart problems, reduced appetite, headache, nausea and vomiting. Other adverse effects noted with short-term use of Hydroxychloroquine include low blood sugar and QT interval prolongation. Idiosyncratic hypersensitivity reactions have occurred.
== Clinical significance == The members of the HtrA family of proteases have been shown playing critical roles in cell physiology and being involved in several pathological processes including cancer and neurodegenerative disease. Strong evidences supported HtrA2's involvement in oncogenesis. This protein is widely expressed in a variety of cancer cell lines, Analysis of biopsy samples showed changes in expression of HtrA2 in cancer tissues compared with normal tissues. HtrA2 has recently been identified as a gene related to Parkinson's disease. Mutations in Htra2 have been found in patients with Parkinson's disease. Additionally, mice lacking HtrA2 have a parkinsonian phenotype. This suggests that HtrA2 is linked to Parkinson's disease progression in humans and mice.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.